期刊文献+

氯氮平与阿立哌唑治疗精神分裂症临床疗效的对照研究 被引量:2

Controlled study of clozapine and aripiprazole in the treatment of schizophrenia
下载PDF
导出
摘要 目的评价阿立哌唑与氯氮平治疗精神分裂症的疗效与不良反应。方法将78例精神分裂症患者随机分为2组,分别予以氯氮平及阿立哌唑治疗,疗程8周。采用潘氏量表、副反应量表评定临床疗效和不良反应。结果两组临床疗效比较无显著性差异(P>0.05)。两组PANSS评分分析,治疗前后比较有显著性差异(P<0.05),两组间比较无显著性差异(P>0.05)。结论阿立哌唑与氯氮平治疗精神分裂症均有效,前者不良反应少,安全性高。 Objective To compare the curative effects and side effects of aripiprazole and clozapine on schizophrenia.Methods 78 schizophrenics were randomly divided into aripiprazole and clozapine groups.The therapeutic effects and side effects were assessed with the Positive And Negative Symptom Scale(PANSS) and Treatment Emergent Symptom Scale(TESS) before and at the end of 2nd,4th and 8th week of treatment respectively.Results There was no significant difference in curative effect and PANSS between two groups,but there were significant differences before and after inpatient treatment.Aripiprazole group had fewer side effect than clozapine group.Conclusion Aripiprazole and clozapine are effective in the treatment of schizophrenia.Aripiprazole has fewer side effects.
作者 安成革
出处 《实用药物与临床》 CAS 2008年第4期213-214,共2页 Practical Pharmacy and Clinical Remedies
关键词 氯氮平 阿立哌唑 精神分裂症 Clozapine Aripiprazole Schizophrenia
  • 相关文献

参考文献4

二级参考文献26

  • 1[1]Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 ( 1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995 Jul, 274( 1 ) :329 ~ 336
  • 2[2]Fleishhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural transm Suppl, 2003, 105 ~ 117
  • 3[3]Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[ 4-( 4-phenyl-1-piperazinyl ) butoxy ]-3, 4-dthydro-2 (1H)-quinolinone derivatives. J Med Chem, 1998 Feb, 41 : 658 ~667
  • 4[4]Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacolgy (Berl), 1999 Sep, 146(2) : 139 ~ 143
  • 5[5]Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropschopharmacolgy, 1999 Jun, 20(6) : 612~627
  • 6[6]Inoue A, Seto M, Sugita S, et al. differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat ptiuitary. Brain Res Mol Brain Res, 1998 apr, 55 : 285 ~292
  • 7[7]Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.Neuropsychopharmacology, 2003 May
  • 8[8]Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT ( 1 A) receptor. Eur J Pharmacol, 2002 Apr 26,441(3) : 137 ~140
  • 9[9]Goodnick P J, Jerry JM. aripiprazole: profile on efficacy and safety.Expert Opin Pharmacother, 2002 Dec, 3(12) : 1773 ~ 1781
  • 10[10]Stahl SM. dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry, 2001 Nov, 62 (11 ) : 841 ~ 842

共引文献250

同被引文献69

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部